Respiratory

CHMP recommends AstraZeneca’s Tezspire for approval to treat severe asthma

AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency as an add-on therapy in patients aged 12 years and above suffering with severe asthma.

Chinese biotech firm Therorna closes $42m Series A financing round

China-based biotech company Therorna has secured $42m in a Series A financing round to support its growth and fuel product pipeline development.

Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Boehringer Ingelheim’s new oral therapy, BI 1015550, to treat patients with idiopathic pulmonary fibrosis (IPF).

Pfizer to deliver 2.5 million additional doses of Covid-19 pill to UK

Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.

Merck and Ridgeback initiate Covid-19 trial of oral antiviral therapeutic

Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection.

Dyadic and Medytox to co-develop Covid-19 variant fighting vaccines

US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines.

NIH study finds severe Covid-19 during pregnancy leads to complications

Preliminary findings from a study funded by the National Institutes of Health (NIH) has found that pregnant women with severe Covid-19 symptoms had a higher risk of complications during and after pregnancy.

GE researchers begin in-depth study to understand Covid-19 impact on lungs

Bioscience researchers at GE Research have begun an in-depth study to better understand the impact of the Covid-19 virus on the lungs.

US DOD to fund Humanetics’ new drug test against Covid-19

The US Department of Defense (DOD) has approved the funding of US-based private pharmaceutical firm Humanetics to test its drug candidate BIO 300 in treating pulmonary inflammation triggered by COVID-19.